Complejo Hospitalario Universitario la Coruna

A Coruña, Spain

Complejo Hospitalario Universitario la Coruna

A Coruña, Spain
SEARCH FILTERS
Time filter
Source Type

Diaz-Rubio E.,Hospital Clinico San Carlos | Gomez-Espana A.,Hospital Reina Sofia | Massuti B.,Hospital General | Sastre J.,Hospital Clinico San Carlos | And 21 more authors.
Oncologist | Year: 2012

Purpose. The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with metastatic colorectal cancer (mCRC). Patients and Methods. Patients were randomly assigned to receive six cycles of bevacizumab, capecitabine, and oxaliplatin every 3 weeks followed by XELOX plus bevacizumab or bevacizumab alone until progression. The primary endpoint was the progression-free survival (PFS) interval; secondary endpoints were the overall survival (OS) time, objective response rate (RR), time to response, duration of response, and safety. Results. The intent-to-treat population comprised 480 patients (XELOX plus bevacizumab, n = 239; bevacizumab, n = 241); there were no significant differences in baseline characteristics. The median follow-up was 29.0 months (range, 0-53.2 months). There were no statistically significant differences in the median PFS or OS times or in the RR between the two arms. The most common grade 3 or 4 toxicities in the XELOX plus bevacizumab versus bevacizumab arms were diarrhea, hand-foot syndrome, and neuropathy. Conclusion. Although the noninferiority of bevacizumab versus XELOX plus bevacizumab cannot be confirmed, we can reliably exclude a median PFS detriment >3 weeks. This study suggests that maintenance therapy with singleagent bevacizumab may be an appropriate option following induction XELOX plus bevacizumab in mCRC patients. © AlphaMed Press.


del Carmen Martinez-Ballesta M.,CSIC - Center of Edafology and Applied Biology of the Segura | Bou G.,Complejo Hospitalario Universitario La Coruna | Carvajal M.,CSIC - Center of Edafology and Applied Biology of the Segura
Phytochemistry Reviews | Year: 2013

Aquaporins (AQPs) are integral membrane proteins that serve as selective pores through which water and small solutes cross the plasma membranes of many human tissue and cell types. They have been identified in epithelia and endothelia involved in fluid transport, such as kidney tubules and glandular epithelia, glial cells, epidermis, and adipocytes. The pathophysiological roles of these proteins and the primary and secondary involvement of AQPs are becoming apparent in diverse clinical disorders, from diabetes insipidus to various forms of edema. The advanced understanding of aquaporin biology, from the structural determinants of channel permeability to the assignment of their physiological function in different organs, will allow the use of AQPs as targets for the therapy of a wide array of diseases. In this review, the mode of action of clinically-effective plant formulae on human AQPs-related diseases at the molecular, cellular, and organism levels is explored. The use of pharmacological plant-derived compounds as a possible strategy in the therapy of diseases related to altered water homeostasis should stimulate debate and further research objectives. © 2013 Springer Science+Business Media Dordrecht.


Acosta J.,Hospital Universitario 12 Of Octubre | Merino M.,Complejo Hospitalario Universitario La Coruna | Viedma E.,Hospital Universitario 12 Of Octubre | Poza M.,Complejo Hospitalario Universitario La Coruna | And 4 more authors.
Emerging Infectious Diseases | Year: 2011

In February 2006, a patient colonized with a multi drugresistant sequence type 56 Acinetobacter baumannii strain was admitted to a hospital in Madrid, Spain. This strain spread rapidly and caused a large outbreak in the hospital. Clinicians should be alert for this strain because its spread would have serious health consequences.


Molina Vazquez M.E.,Complejo Hospitalario Universitario La Coruna
Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica | Year: 2010

Dysfunctional voiding syndrome in children is characterized by a pattern of dysfunctional bladder emptying due to an active contraction of the external sphincter during micturition. Diagnosis is based on electromyographic and flowmetry results. The treatment is focused on relaxing the external sphincter during micturition where biofeedback is the treatment of choice. By the moment there are still centres without this possibility, alpha blockers are an alternative. To determine the efficacy of alpha blockers as an alternative to biofeedback as a therapeutic possibility. We included a total of 17 children with dysfunctional voiding syndrome and carried out a retrospective study. We registered age, symptoms at diagnosis, presence of associated urologic problems, flowmetry results pre and post-treatment, type of treatment used and its effectiveness comparing patients treated with alpha blockers and those who are starting to deal with biofeedback. There were 12 girls and 5 boys. The mean age at diagnosis was 4.9 years old, 88% of these children related enuresis, diurnal urinary incontinence and urgency, 57% of them had also urinary infections, 63% constipation, 36% had psychosocial problems. Ten patients were treated with alpha-antagonists: 6 with Tamsulosin and 4 with Doxazosin. They followed this treatment an average of 5.8 months, range between 2 and 12 months. Five patients were treated with biofeedback. All cases had an abnormal pelvic electromyography. Patients treated with alpha-blockers achieved a 70% of electromyographic improvement with a 70% of recurrence. In children treated with biofeedback we got improvement in 80% with no recurrence. After alpha blocker therapy, maximum flow rates and average flow values were better but not statistically significant, this difference was significant with biofeedback. A patient treated with Tamsulosin left treatment due to hypotension, 2 patients left Doxazosin because of dizziness. Alpha-blockers are effective in the treatment of dysfunctional voiding syndrome with a high percentage of recurrence. They can be an alternative to biofeedback but this one is the effective and definitive treatment.


Mallo S.,Complejo Hospitalario Universitario La Coruna | Perez-Llarena F.J.,Complejo Hospitalario Universitario La Coruna | Kerff F.,University of Liège | Soares N.C.,Complejo Hospitalario Universitario La Coruna | And 2 more authors.
Journal of Antimicrobial Chemotherapy | Year: 2010

Objectives: A natural variant of the AmpC enzyme from Escherichia coli HKY28 with a tripeptide deletion (Gly-286/Ser-287/Asp-288) was recently described. The isolate produced an inhibitor-sensitive AmpC β-lactamase variant that also conferred higher than usual levels of resistance to ceftazidime in the E. coli host. To demonstrate whether this is true in other class C β-lactamase enzymes, we deleted the equivalent tripeptide in the FOX-4 plasmid-mediated class C β-lactamase. Methods: By site-directed mutagenesis, we deleted the tripeptide Gly-306/Asn-307/Ser-308 of FOX-4, thus generating FOX-4(ΔGNS). The enzymes (FOX-4 wild-type and ΔGNS) were purified and kinetic parameters (kcat, Km, kcat/Km) as well as IC50 values of several β-lactams were assessed. Modelling studies were also performed. Results: FOX-4(ΔGNS) did not increase the catalytic efficiency towards ceftazidime, although it conferred a slight increase in the susceptibility to β-lactamase inhibitors. There was also a noteworthy decrease in the cefoxitin MIC with the FOX-4(ΔGNS) mutant (from 512 to 16 mg/L) as well as a 10-fold decrease in kcat/Km towards imipenem, which revealed specific structural features. Conclusions: Although deletions in the R2-loop are able to extend the substrate spectrum of class C enzymes, the present results do not confirm this hypothesis in FOX-4. The FOX-4 R2 site would already be wide enough to accommodate antibiotic molecules, and thus any amino acid replacement or deletion at this location would not affect the hydrolytic efficiency towards b-lactams and would have a less drastic effect on the susceptibility to β-lactamase inhibitors. © The Author 2010. Published by Oxford University Press.


Merino M.,Complejo Hospitalario Universitario La Coruna | Perez-Llarena F.J.,Complejo Hospitalario Universitario La Coruna | Kerff F.,University of Liège | Poza M.,Complejo Hospitalario Universitario La Coruna | And 6 more authors.
Journal of Antimicrobial Chemotherapy | Year: 2010

Objectives: The new metallo-β-lactamase VIM-13 has been recently characterized. In comparison with the VIM-1 enzyme, VIM-13 showed 19 amino acid differences, 2 of which were located in the active site centre. The main objective of the present study was to assess whether differences between VIM-1 and VIM-13 β-lactamases in the active site, at His224Leu and Ser228Arg, are necessary and sufficient to explain the microbiological and biochemical differences between the two enzymes. Methods: Single mutants VIM-13 (Leu224His) and VIM-13 (Arg228Ser) and double mutant VIM-13 (Leu224His, Arg228Ser) were created by site-directed mutagenesis with the blaVIM-13 gene as template. VIM-1, VIM-13 and VIM-13 (Leu224His, Arg228Ser) were purified by affinity chromatography, and kinetic parameters for these enzymes were obtained with ceftazidime, cefepime and ampicillin. Results: Ceftazidime and cefepime MICs (mg/L) for Escherichia coli TG1 expressing VIM-1, VIM-13, VIM-13 (Leu224His), VIM-13 (Arg228Ser) and VIM-13 (Leu224His, Arg228Ser) were .256 and 64, 6 and 4, 8 and 1, .256 and 8, and .256 and 48, respectively. VIM-1, VIM-13 and VIM-13 (Leu224His, Arg228Ser) revealed kcat/Km values (M-1 s-1) for ceftazidime of 3.7 E4, 1.9 E4 and 10 E4, respectively, and revealed kcat/Km values for cefepime of 3.5 E5,3E4 and 1.5 E5, respectively. Conclusions: Overall, the results showed that the two residues located in the L3 loop are sufficient to confer the substrate specificity of each enzyme, thus highlighting the importance of the L3 loop of the active site in the evolution of VIM-type metallo-β-lactamases. © The Author 2010. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.


Martin L.B.,Complejo Hospitalario Universitario la Coruna | Valbuena L.,Complexo Hospitalario Universitario Of runa | Castanon L.B.,Complejo Hospitalario Universitario la Coruna
Archivos Espanoles de Urologia | Year: 2015

OBJECTIVE: To report two cases of urachal adenocarcinoma and to review the published literature. METHODS / RESULTS: We present a review of our urachal carcinoma cases from a third level hospital between 1990-2011 in an area of 520.000 inhabitants. Both cases were middle aged men, consulting for repeated urine infections, and abdominal mass with hematuria and mucous discharge through the urethra. They were treated initially with partial cystectomy and adjuvant treatment with chemotherapy in one case, and chemo and radiotherapy in the other. The first case died in 3 years and the other is still alive after 4 years of follow up. CONCLUSIONS: Urachal adenocarcinomas of the bladder are rare tumors the natural history of which has not changed during the last years. Open partial cystectomy with en bloc resection of the bladder dome, urachus and the umbilicus is the standard treatment in localized stages, although minimal invasive techniques appear to have the same oncological outcomes. Pelvic lymphadenectomy is advised. Most of the patients are diagnosed at an advanced local or metastatic stage. There is a need to improve diagnostic techniques for early treatment and to find new chemotherapy protocols that can help to improve these patients survival.


Martin L.B.,Complejo Hospitalario Universitario La Coruna | Pereira P.P.,Complejo Hospitalario Universitario La Coruna | Lista F.S.,Service of Urology | Castanon L.B.,Complejo Hospitalario Universitario La Coruna
Archivos Espanoles de Urologia | Year: 2013

Objective: To report a case of a mesothelioma of the tunica vaginalis and to review the published literature. Methods/Results: A 61-year-old patient complained of one-month increase of right scrotum size with pain. An ultrasound showed a right hydrocele with a mass attached to the tunica vaginalis. He didn't refer any urological history or known exposure to asbestos. Blood levels of tumor markers (alpha-fetoprotein and beta-HCG) were within normal limits. We performed a radical inguinal orchiectomy with an en-bloc resection of the tunica vaginalis. The pathology described a potentially malignant biphasic mesothelioma. The patient has remained asymptomatic with negative extension studies after 10 years of follow up. Conclusions: Paratesticular mesotheliomas are rare tumors (approximately 250 cases reported) with uncertain etiology (only 30-40% are associated with asbestos exposure). The age range is between 50-70 years. Its presentation is usually as a scrotal mass with recurrent reactive hydrocele, which may delay early diagnosis. During surgery, intraoperative biopsy is recommended. It is important to do a differential diagnosis with other benign diseases. Treatment is only curative in early stages with radical orchidectomy and resection in-block of the tunica vaginalis. Despite being multidisciplinary, it is not curative in most cases due to rapid local and distant spread.


Soares N.C.,Complejo Hospitalario Universitario la Coruna | Cabral M.P.,Complejo Hospitalario Universitario la Coruna | Gayoso C.,Complejo Hospitalario Universitario la Coruna | Mallo S.,Complejo Hospitalario Universitario la Coruna | And 3 more authors.
Journal of Proteome Research | Year: 2010

Acinetobacter baumannii is an opportunistic pathogen that has been associated with severe infections and outbreaks in hospitals. At present, very little is known about the biology of this bacterium, particularly as regards mechanisms of adaptation, persistence and virulence. To investigate the growth phase-dependent regulation of proteins in this microorganism, we analyzed the proteomic pattern of A. baumannii ATCC 17978 at different stages of in vitro growth. In this study, proteomics analyses were conducted using 2-DE and MALDI-TOF/TOF complemented by iTRAQ LC-MS/MS. Here we have identified 107 differentially expressed proteins. We highlight the induction of proteins associated with signaling, putative virulence factors and response to stress (including oxidative stress). We also present evidence that ROS (O 2- and OH-) and RNI (ONOO-) accumulate during late stages of growth. Further assays demonstrated that stationary cells survive at high concentrations of H2O2 (30 mM), the O2- donor menadione (500 μ) or the NO donor sodium nitroprusside (1 mM), and showed a higher survival rate against several bactericidal antibiotics. The growth phase-dependent changes observed in the A. baumannii proteome are discussed within a context of adaptive biological responses, including those related to ROS and RNI stress. © 2010 American Chemical Society.


Fernandez Sueiro J.L.,Complejo Hospitalario Universitario La Coruna | Gonzalez Diaz De Rabago E.,Complejo Hospitalario Universitario La Coruna
Reumatologia Clinica | Year: 2010

Spinal involvement in PsA is a controversial issue. Currently, in spite of clinical recognition of axial involvement in axial PsA, there is a lack of consensus that impedes elaborating a definition for axial Psa. Recent advances in classification, clinical features, outcome measures and therapeutics are reviewed in this paper. © 2009 Elsevier España, S.L. All rights reserved.

Loading Complejo Hospitalario Universitario la Coruna collaborators
Loading Complejo Hospitalario Universitario la Coruna collaborators